Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""recurrence"" wg kryterium: Temat


Tytuł :
α-Fetoprotein as a predictor of outcome for children with germ cell tumors: A report from the Malignant Germ Cell International Consortium.
Autorzy :
O'Neill AF; Dana-Farber Cancer Institute, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts.
Xia C; Statistics and Data Center, Children's Oncology Group, Monrovia, California.
Krailo MD; Keck School of Medicine, University of Southern California, Los Angeles, California.
Shaikh F; Hospital for Sick Children, University of Toronto, Toronto, Canada.
Pashankar FD; Yale University School of Medicine, New Haven, Connecticut.
Billmire DF; Indiana University School of Medicine, Indianapolis, Indiana.
Olson TA; Aflac Cancer and Blood Disorders Service, Emory University School of Medicine, Atlanta, Georgia.
Amatruda JF; University of Texas Southwestern Medical Center, Dallas, Texas.
Villaluna D; Statistics and Data Center, Children's Oncology Group, Monrovia, California.
Huang L; Statistics and Data Center, Children's Oncology Group, Monrovia, California.
Malogolowkin M; Comprehensive Cancer Center, University of California Davis, Sacramento, California.
Rodriguez-Galindo C; St. Jude Children's Research Hospital, Memphis, Tennessee.
Frazier AL; Dana-Farber Cancer Institute, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts.
Pokaż więcej
Źródło :
Cancer [Cancer] 2019 Oct 15; Vol. 125 (20), pp. 3649-3656. Date of Electronic Publication: 2019 Jul 29.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Prognosis*
Neoplasm Recurrence, Local/*genetics
Neoplasms, Germ Cell and Embryonal/*genetics
alpha-Fetoproteins/*genetics
Adolescent ; Adult ; Biomarkers, Tumor/genetics ; Child ; Child, Preschool ; Disease-Free Survival ; Female ; Humans ; Infant ; Male ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/pathology ; Neoplasms, Germ Cell and Embryonal/drug therapy ; Neoplasms, Germ Cell and Embryonal/pathology ; Recurrence ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Disparities in risk perception of thyroid cancer recurrence and death.
Autorzy :
Chen DW; Division of Metabolism, Endocrinology, and Diabetes, University of Michigan, Ann Arbor, Michigan.
Reyes-Gastelum D; Division of Metabolism, Endocrinology, and Diabetes, University of Michigan, Ann Arbor, Michigan.
Wallner LP; Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.
Papaleontiou M; Division of Metabolism, Endocrinology, and Diabetes, University of Michigan, Ann Arbor, Michigan.
Hamilton AS; Department of Preventive Medicine, University of Southern California, Los Angeles, California.
Ward KC; Department of Epidemiology, Emory University, Atlanta, Georgia.
Hawley ST; Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan.
Zikmund-Fisher BJ; Department of Health Behavior and Health Education, University of Michigan, Ann Arbor, Michigan.; Division of General Internal Medicine, University of Michigan, Ann Arbor, Michigan.
Haymart MR; Division of Metabolism, Endocrinology, and Diabetes, University of Michigan, Ann Arbor, Michigan.
Pokaż więcej
Źródło :
Cancer [Cancer] 2020 Apr 01; Vol. 126 (7), pp. 1512-1521. Date of Electronic Publication: 2019 Dec 23.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
MeSH Terms :
Health Knowledge, Attitudes, Practice*/ethnology
Neoplasm Recurrence, Local*/psychology
Thyroid Neoplasms*/psychology
Cancer Survivors/*psychology
Adult ; Aged ; Anxiety/epidemiology ; Anxiety/etiology ; Female ; Georgia ; Humans ; Male ; Middle Aged ; Perception ; Quality of Life ; SEER Program
Czasopismo naukowe
Tytuł :
A phase 1 trial of everolimus and bevacizumab in children with recurrent solid tumors.
Autorzy :
Santana VM; Department of Oncology, St. Jude Children's Research Hospital and Comprehensive Cancer Center, Memphis, Tennessee.
Sahr N; Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee.
Tatevossian RG; Diagnostic Biomarkers Shared Resource, Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Jia S; Diagnostic Biomarkers Shared Resource, Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee.
Campagne O; Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee.
Sykes A; Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee.
Stewart CF; Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee.
Furman WL; Department of Oncology, St. Jude Children's Research Hospital and Comprehensive Cancer Center, Memphis, Tennessee.
McGregor LM; Department of Pediatrics, Penn State University College of Medicine, Hershey, Pennsylvania.
Pokaż więcej
Źródło :
Cancer [Cancer] 2020 Apr 15; Vol. 126 (8), pp. 1749-1757. Date of Electronic Publication: 2020 Jan 22.
Typ publikacji :
Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Angiogenesis Inhibitors/*therapeutic use
Antineoplastic Agents/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Bevacizumab/*therapeutic use
Everolimus/*therapeutic use
Neoplasm Recurrence, Local/*drug therapy
Neoplasms/*drug therapy
Adolescent ; Child ; Child, Preschool ; Female ; Humans ; Male ; Maximum Tolerated Dose ; Neoplasm Recurrence, Local/pathology ; Neoplasms/pathology ; Prognosis ; Progression-Free Survival
Czasopismo naukowe
Tytuł :
High-dose chemotherapy plus peripheral blood stem cell transplantation for patients with relapsed germ cell tumors and active brain metastases.
Autorzy :
Kalra M; Division of Hematology/Oncology, Indiana University Simon Cancer Center, Indianapolis, Indiana.
Adra N; Division of Hematology/Oncology, Indiana University Simon Cancer Center, Indianapolis, Indiana.
Hanna N; Division of Hematology/Oncology, Indiana University Simon Cancer Center, Indianapolis, Indiana.
Abonour R; Division of Hematology/Oncology, Indiana University Simon Cancer Center, Indianapolis, Indiana.
Einhorn LH; Division of Hematology/Oncology, Indiana University Simon Cancer Center, Indianapolis, Indiana.
Pokaż więcej
Źródło :
Cancer [Cancer] 2020 Mar 15; Vol. 126 (6), pp. 1202-1207. Date of Electronic Publication: 2019 Nov 19.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Peripheral Blood Stem Cell Transplantation*
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Brain Neoplasms/*therapy
Neoplasm Recurrence, Local/*therapy
Neoplasms, Germ Cell and Embryonal/*therapy
Adolescent ; Adult ; Biomarkers, Tumor/blood ; Brain Neoplasms/blood ; Brain Neoplasms/mortality ; Brain Neoplasms/secondary ; Carboplatin/administration & dosage ; Cause of Death ; Chorionic Gonadotropin/blood ; Combined Modality Therapy/methods ; Cranial Irradiation ; Drug Administration Schedule ; Etoposide/administration & dosage ; Humans ; Kaplan-Meier Estimate ; Male ; Metastasectomy ; Middle Aged ; Neoplasm Recurrence, Local/blood ; Neoplasm Recurrence, Local/mortality ; Neoplasms, Germ Cell and Embryonal/blood ; Neoplasms, Germ Cell and Embryonal/mortality ; Neoplasms, Germ Cell and Embryonal/secondary ; Platelet Count ; Platelet Transfusion ; Radiosurgery ; Young Adult ; alpha-Fetoproteins/analysis
Czasopismo naukowe
Tytuł :
The impact of new systemic therapies on survival and time on hormonal treatment in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: A population-based study in British Columbia from 2003 to 2013.
Autorzy :
Le D; Department of Medical Oncology, Fraser Valley Cancer Centre, BC Cancer, Surrey, British Columbia, Canada.
Speers C; Cancer Surveillance and Outcomes, BC Cancer, Vancouver, British Columbia, Canada.
Thompson L; Cancer Surveillance and Outcomes, BC Cancer, Vancouver, British Columbia, Canada.
Gondara L; Cancer Surveillance and Outcomes, BC Cancer, Vancouver, British Columbia, Canada.
Nichol A; Department of Radiation Oncology, Vancouver Centre, BC Cancer, Vancouver, British Columbia, Canada.
Lohrisch C; Department of Medical Oncology, Vancouver Centre, BC Cancer, Vancouver, British Columbia, Canada.
Pokaż więcej
Źródło :
Cancer [Cancer] 2020 Mar 01; Vol. 126 (5), pp. 971-977. Date of Electronic Publication: 2019 Nov 21.
Typ publikacji :
Journal Article
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Breast Neoplasms/*mortality
Neoadjuvant Therapy/*mortality
Neoplasm Recurrence, Local/*mortality
Receptor, ErbB-2/*metabolism
Receptors, Estrogen/*metabolism
Receptors, Progesterone/*metabolism
Adult ; Aged ; Aged, 80 and over ; Biomarkers, Tumor/metabolism ; Breast Neoplasms/drug therapy ; Breast Neoplasms/metabolism ; Breast Neoplasms/pathology ; Female ; Follow-Up Studies ; Humans ; Middle Aged ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/metabolism ; Neoplasm Recurrence, Local/pathology ; Prognosis ; Prospective Studies ; Retrospective Studies ; Survival Rate
Czasopismo naukowe
Tytuł :
Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers.
Autorzy :
Song Y; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.
Barry WT; Harvard Medical School, Boston, Massachusetts.; Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Seah DS; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
Tung NM; Harvard Medical School, Boston, Massachusetts.; Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Garber JE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.
Lin NU; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Harvard Medical School, Boston, Massachusetts.
Pokaż więcej
Źródło :
Cancer [Cancer] 2020 Jan 15; Vol. 126 (2), pp. 271-280. Date of Electronic Publication: 2019 Oct 03.
Typ publikacji :
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
BRCA1 Protein/*genetics
BRCA2 Protein/*genetics
Breast Neoplasms/*pathology
Central Nervous System Neoplasms/*epidemiology
Neoplasm Recurrence, Local/*epidemiology
Adult ; Aged ; Aged, 80 and over ; Breast Neoplasms/genetics ; Breast Neoplasms/mortality ; Central Nervous System Neoplasms/genetics ; Central Nervous System Neoplasms/secondary ; Female ; Germ-Line Mutation ; Heterozygote ; Humans ; Lymph Nodes/pathology ; Lymphatic Metastasis/genetics ; Middle Aged ; Neoplasm Recurrence, Local/genetics ; Retrospective Studies ; Survival Analysis ; Young Adult
Czasopismo naukowe
Tytuł :
Sorafenib and omacetaxine mepesuccinate as a safe and effective treatment for acute myeloid leukemia carrying internal tandem duplication of Fms-like tyrosine kinase 3.
Autorzy :
Zhang C; Division of Haematology, Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Lam SSY; Division of Haematology, Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Leung GMK; Division of Haematology, Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Tsui SP; Division of Haematology, Department of Pathology, Queen Mary Hospital, Hong Kong, China.
Yang N; Division of Haematology, Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Ng NKL; Division of Haematology, Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Ip HW; Division of Haematology, Department of Pathology, Queen Mary Hospital, Hong Kong, China.
Au CH; Department of Pathology, Hong Kong Sanatorium and Hospital, Hong Kong, China.
Chan TL; Department of Pathology, Hong Kong Sanatorium and Hospital, Hong Kong, China.
Ma ESK; Department of Pathology, Hong Kong Sanatorium and Hospital, Hong Kong, China.
Yip SF; Department of Medicine, Tuen Mun Hospital, Hong Kong, China.
Lee HKK; Department of Medicine, Princess Margaret Hospital, Hong Kong, China.
Lau JSM; Department of Medicine, Queen Elizabeth Hospital, Hong Kong, China.
Luk TH; Department of Medicine, Queen Elizabeth Hospital, Hong Kong, China.
Li W; Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong, China.
Kwong YL; Division of Haematology, Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Leung AYH; Division of Haematology, Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Pokaż więcej
Źródło :
Cancer [Cancer] 2020 Jan 15; Vol. 126 (2), pp. 344-353. Date of Electronic Publication: 2019 Oct 03.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Homoharringtonine/*administration & dosage
Leukemia, Myeloid, Acute/*therapy
Neoplasm Recurrence, Local/*therapy
Sorafenib/*administration & dosage
fms-Like Tyrosine Kinase 3/*genetics
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/pharmacokinetics ; Disease Progression ; Disease-Free Survival ; Drug Administration Schedule ; Drug Resistance, Neoplasm ; Drug Synergism ; Exons/genetics ; Female ; Gene Duplication ; Hematopoietic Stem Cell Transplantation ; Homoharringtonine/adverse effects ; Homoharringtonine/pharmacokinetics ; Humans ; Leukemia, Myeloid, Acute/genetics ; Leukemia, Myeloid, Acute/mortality ; Leukemia, Myeloid, Acute/pathology ; Male ; Middle Aged ; Neoplasm Recurrence, Local/genetics ; Neoplasm Recurrence, Local/mortality ; Neoplasm Recurrence, Local/pathology ; Remission Induction/methods ; Sorafenib/adverse effects ; Sorafenib/pharmacokinetics ; Transplantation, Homologous ; Young Adult ; fms-Like Tyrosine Kinase 3/antagonists & inhibitors ; fms-Like Tyrosine Kinase 3/pharmacokinetics
Czasopismo naukowe
Tytuł :
Unrealistic parental expectations for cure in poor-prognosis childhood cancer.
Autorzy :
Mack JW; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Division of Population Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts.; Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.
Cronin AM; Division of Population Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts.
Uno H; Division of Population Sciences, Dana-Farber Cancer Institute, Boston, Massachusetts.
Shusterman S; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.
Twist CJ; Pediatric Experimental Therapeutics, Department of Pediatric Oncology, Roswell Park Cancer Institute, Buffalo, New York.
Bagatell R; Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.
Rosenberg A; Department of Pediatric Hematology/Oncology, Seattle Children's Research Institute, Seattle, Washington.; Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington.
Marachelian A; Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, California.
Granger MM; Hematology and Oncology Center, Cook Children's Medical Center, Fort Worth, Texas.
Glade Bender J; Department of Pediatric Oncology, Memorial Sloan Kettering Cancer Center, New York, New York.
Baker JN; Division of Quality of Life and Palliative Care, St Jude Children's Research Hospital, Memphis, Tennessee.
Park J; Department of Pediatric Hematology/Oncology, Seattle Children's Research Institute, Seattle, Washington.; Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington.
Cohn SL; Department of Pediatrics, Comer Children's Hospital, University of Chicago, Chicago, Illinois.
Levine A; Emory University School of Medicine, Atlanta, Georgia.
Taddei S; Department of Social Work, Massachusetts General Hospital, Boston, Massachusetts.
Diller LR; Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.; Division of Pediatric Hematology/Oncology, Boston Children's Hospital, Boston, Massachusetts.
Pokaż więcej
Źródło :
Cancer [Cancer] 2020 Jan 15; Vol. 126 (2), pp. 416-424. Date of Electronic Publication: 2019 Oct 04.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Attitude to Death*
Neoplasm Recurrence, Local/*mortality
Neuroblastoma/*mortality
Palliative Care/*psychology
Parents/*psychology
Adult ; Child ; Child, Preschool ; Clinical Trials as Topic ; Communication ; Decision Making ; Emotions ; Female ; Humans ; Male ; Motivation ; Neoplasm Recurrence, Local/psychology ; Neoplasm Recurrence, Local/therapy ; Neuroblastoma/psychology ; Neuroblastoma/therapy ; Physician-Patient Relations ; Prognosis ; Prospective Studies ; Quality of Life ; Surveys and Questionnaires/statistics & numerical data ; Therapies, Investigational/psychology
Czasopismo naukowe
Tytuł :
Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure.
Autorzy :
Ayers EC; Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.
Li S; Department of Hematopathology, The University of Texas MD Anderson Cancer, Houston, Texas.
Medeiros LJ; Department of Hematopathology, The University of Texas MD Anderson Cancer, Houston, Texas.
Bond DA; Department of Internal Medicine, The Ohio State University Cancer Center, Columbus, Ohio.
Maddocks KJ; Department of Hematology, The Ohio State University Cancer Center, Columbus, Ohio.
Torka P; Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Mier Hicks A; Roswell Park Comprehensive Cancer Center, Buffalo, New York.
Curry M; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland.
Wagner-Johnston ND; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland.
Karmali R; Department of Medicine, Division of Hematology/Oncology, Northwestern University Feinberg.; School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois.
Behdad A; Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Fakhri B; Washington University School of Medicine, St. Louis, Missouri.
Kahl BS; Washington University School of Medicine, St. Louis, Missouri.
Churnetski MC; Department of Hematology, Winship Cancer Institute, Emory University, Atlanta, Georgia.; Department of Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia.
Cohen JB; Department of Hematology, Winship Cancer Institute, Emory University, Atlanta, Georgia.
Reddy NM; Department of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, Tennessee.
Modi D; Karmanos Cancer Institute/Wayne State University, Detroit, Michigan.
Ramchandren R; Hematology-Oncology, Karmanos Cancer Institute/Wayne State University, Detroit, Michigan.
Howlett C; Deparrment of Pharmacy and Clinical Services, John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, New Jersey.
Leslie LA; John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, New Jersey.
Cytryn S; New York University Perlmutter Cancer Center, New York, New York.
Diefenbach CS; New York University Perlmutter Cancer Center, New York, New York.
Faramand R; Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, Florida.
Chavez JC; Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, Florida.
Olszewski AJ; The Warren Alpert Medical School of Brown University, Providence, Rhode Island.; Division of Hematology-Oncology, Rhode Island Hospital, Providence, Rhode Island.
Liu Y; Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Barta SK; Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.; Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Mukhija D; Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.
Hill BT; Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.
Ma H; Center for Lymphoid Malignancies, Department of Medicine, and Department of Pathology and Cell Biology, Columbia University Medical Center , New York.
Amengual JE; Division of Hematology and Oncology, Department of Medicine, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York.
Nathan S; Rush University Medical Center, Chicago, Illinois.
Assouline SE; Medicine and Oncology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada.
Orellana-Noia VM; University of Virginia, Charlottesville, Virginia.
Portell CA; Hematology and Oncology, University of Virginia, Charlottesville, Virginia.
Chandar A; Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey.
David KA; Rush University Medical Center, Chicago, Illinois.
Giri A; Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina.
Hess BT; Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina.
Landsburg DJ; Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.
Pokaż więcej
Źródło :
Cancer [Cancer] 2020 Jan 15; Vol. 126 (2), pp. 293-303. Date of Electronic Publication: 2019 Sep 30.
Typ publikacji :
Journal Article; Multicenter Study
MeSH Terms :
Hematopoietic Stem Cell Transplantation*
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Lymphoma, Large B-Cell, Diffuse/*therapy
Neoplasm Recurrence, Local/*therapy
Salvage Therapy/*methods
Adult ; Antineoplastic Combined Chemotherapy Protocols/pharmacology ; Drug Resistance, Neoplasm ; Female ; Follow-Up Studies ; Humans ; Kaplan-Meier Estimate ; Lymphoma, Large B-Cell, Diffuse/mortality ; Lymphoma, Large B-Cell, Diffuse/pathology ; Male ; Middle Aged ; Neoplasm Recurrence, Local/mortality ; Neoplasm Recurrence, Local/pathology ; Progression-Free Survival ; Retrospective Studies ; Salvage Therapy/standards ; Standard of Care ; Transplantation, Autologous/standards ; Treatment Failure ; Young Adult
Czasopismo naukowe
Tytuł :
The economic research of arsenic trioxide for the treatment of newly diagnosed acute promyelocytic leukemia in China.
Autorzy :
Chen X; Department of Pharmacy, Wuxi Ninth People's Hospital Affiliated to Soochow University and Wuxi Orthopedic Hospital, Wuxi, Jiangsu, China.
Hong Y; Department of Pharmacy, Wuxi Children's Hospital, Wuxi, Jiangsu, China.
Zheng P; Department of Pharmacy, Ningbo No. 6 Hospital, Ningbo, Zhejiang, China.
You X; Department of Pharmacy, Wuxi Ninth People's Hospital Affiliated to Soochow University and Wuxi Orthopedic Hospital, Wuxi, Jiangsu, China.
Feng J; Department of Pharmacy, Wuxi Ninth People's Hospital Affiliated to Soochow University and Wuxi Orthopedic Hospital, Wuxi, Jiangsu, China.
Huang Z; Department of Oncology, Wuxi Ninth People's Hospital Affiliated to Soochow University and Wuxi Orthopedic Hospital, Wuxi, Jiangsu, China.
Wang Y; Department of Pharmacy, Wuxi Children's Hospital, Wuxi, Jiangsu, China.
Pokaż więcej
Źródło :
Cancer [Cancer] 2020 Jan 15; Vol. 126 (2), pp. 311-321. Date of Electronic Publication: 2019 Nov 12.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Cost-Benefit Analysis*
Quality-Adjusted Life Years*
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
Arsenic Trioxide/*therapeutic use
Leukemia, Promyelocytic, Acute/*drug therapy
Neoplasm Recurrence, Local/*epidemiology
Adult ; Antineoplastic Combined Chemotherapy Protocols/economics ; Arsenic Trioxide/economics ; China/epidemiology ; Disease-Free Survival ; Drug Costs ; Female ; Hospitalization/economics ; Hospitalization/statistics & numerical data ; Humans ; Kaplan-Meier Estimate ; Leukemia, Promyelocytic, Acute/diagnosis ; Leukemia, Promyelocytic, Acute/economics ; Leukemia, Promyelocytic, Acute/mortality ; Male ; Markov Chains ; Middle Aged ; Neoplasm Recurrence, Local/economics ; Neoplasm Recurrence, Local/prevention & control ; Remission Induction/methods ; Treatment Failure ; Tretinoin/economics ; Tretinoin/therapeutic use
Czasopismo naukowe
Tytuł :
A phase 2 multicenter study of stereotactic body radiotherapy for hepatocellular carcinoma: Safety and efficacy.
Autorzy :
Jang WI; Department of Radiation Oncology, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.
Bae SH; Department of Radiation Oncology, Soonchunhyang University College of Medicine, Bucheon, Korea.
Kim MS; Department of Radiation Oncology, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.
Han CJ; Department of Internal Medicine, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.
Park SC; Department of Internal Medicine, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.
Kim SB; Department of General Surgery, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.
Cho EH; Department of General Surgery, Korea Institute of Radiological and Medical Sciences, Seoul, Korea.
Choi CW; Department of Radiation Oncology, Dongnam Institute of Radiological and Medical Sciences, Busan, Korea.
Kim KS; Department of Radiation Oncology, Dongnam Institute of Radiological and Medical Sciences, Busan, Korea.
Hwang S; Department of Internal Medicine, Dongnam Institute of Radiological and Medical Sciences, Busan, Korea.
Kim JH; Department of Radiation Oncology, Seoul National University College of Medicine, Seoul, Korea.
Chang AR; Department of Radiation Oncology, Soonchunhyang University College of Medicine, Seoul, Korea.
Park Y; Department of Radiation Oncology, Soonchunhyang University College of Medicine, Seoul, Korea.
Kim ES; Department of Radiation Oncology, Soonchunhyang University College of Medicine, Cheonan, Korea.
Kim WC; Department of Radiation Oncology, Inha University Hospital, Inha University School of Medicine, Incheon, Korea.
Jo S; Department of Radiation Oncology, Haeundae Paik Hospital, Inje University School of Medicine, Busan, Korea.
Park HJ; Department of Radiation Oncology, Hanyang University Hospital, Seoul, Korea.
Pokaż więcej
Źródło :
Cancer [Cancer] 2020 Jan 15; Vol. 126 (2), pp. 363-372. Date of Electronic Publication: 2019 Nov 20.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Carcinoma, Hepatocellular/*radiotherapy
Liver Neoplasms/*radiotherapy
Neoplasm Recurrence, Local/*radiotherapy
Radiation Injuries/*epidemiology
Radiosurgery/*adverse effects
Adult ; Aged ; Aged, 80 and over ; Carcinoma, Hepatocellular/mortality ; Carcinoma, Hepatocellular/pathology ; Dose Fractionation, Radiation ; Female ; Humans ; Liver Neoplasms/mortality ; Liver Neoplasms/pathology ; Male ; Middle Aged ; Neoplasm Recurrence, Local/mortality ; Neoplasm Recurrence, Local/pathology ; Progression-Free Survival ; Prospective Studies ; Radiation Injuries/etiology ; Radiosurgery/methods ; Survival Rate
Czasopismo naukowe
Tytuł :
Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia.
Autorzy :
Rambaldi A; Department of Oncology and Hematology, University of Milan, Bergamo, Italy.
Ribera JM; Clinical Hematology Service, Catalan Institute of Oncology, University Hospital Germans Trias i Pujol, Barcelona, Spain.
Kantarjian HM; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas.
Dombret H; Department of Hematology, Hopital Saint-Louis, Paris Diderot University, Paris, France.
Ottmann OG; Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, United Kingdom.
Stein AS; Gehr Family Center for Leukemia Research, City of Hope, Duarte, California.
Tuglus CA; Amgen, Inc, Thousand Oaks, California.
Zhao X; Amgen, Inc, Thousand Oaks, California.
Kim C; Amgen, Inc, Thousand Oaks, California.
Martinelli G; Scientific Institute of Romagna for the Study and Treatment of Cancer, Meldola, Italy.
Pokaż więcej
Źródło :
Cancer [Cancer] 2020 Jan 15; Vol. 126 (2), pp. 304-310. Date of Electronic Publication: 2019 Oct 18.
Typ publikacji :
Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Hematopoietic Stem Cell Transplantation*
Antibodies, Bispecific/*therapeutic use
Antineoplastic Combined Chemotherapy Protocols/*pharmacology
Neoplasm Recurrence, Local/*drug therapy
Precursor Cell Lymphoblastic Leukemia-Lymphoma/*therapy
Salvage Therapy/*methods
Adolescent ; Adult ; Antibodies, Bispecific/pharmacology ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Drug Resistance, Neoplasm ; Female ; Follow-Up Studies ; Humans ; Male ; Middle Aged ; Neoplasm Recurrence, Local/genetics ; Neoplasm Recurrence, Local/mortality ; Neoplasm Recurrence, Local/pathology ; Philadelphia Chromosome ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/mortality ; Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology ; Propensity Score ; Standard of Care ; Transplantation, Homologous ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Acceptance and commitment therapy for breast cancer survivors with fear of cancer recurrence: A 3-arm pilot randomized controlled trial.
Autorzy :
Johns SA; Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana.; Center for Health Services Research, Regenstrief Institute, Inc., Indianapolis, Indiana.
Stutz PV; Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana.
Talib TL; Center for Health Services Research, Regenstrief Institute, Inc., Indianapolis, Indiana.
Cohee AA; Indiana University School of Nursing, Indianapolis, Indiana.
Beck-Coon KA; Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana.; Indiana University School of Nursing, Indianapolis, Indiana.
Brown LF; Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana.
Wilhelm LR; Department of Behavioral Medicine and Psychiatry, West Virginia University School of Medicine, Charleston, West Virginia.
Monahan PO; Department of Biostatistics, Indiana University School of Medicine, Indianapolis, Indiana.
LaPradd ML; Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana.
Champion VL; Indiana University School of Nursing, Indianapolis, Indiana.
Miller KD; Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana.; Research and Clinical Trials, Indiana University Simon Cancer Center, Indianapolis, Indiana.
Giesler RB; Department of Psychology, Butler University, Indianapolis, Indiana.
Pokaż więcej
Źródło :
Cancer [Cancer] 2020 Jan 01; Vol. 126 (1), pp. 211-218. Date of Electronic Publication: 2019 Sep 20.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Cancer Survivors*
Breast Neoplasms/*psychology
Fear/*psychology
Neoplasm Recurrence, Local/*psychology
Adult ; Aged ; Anxiety/drug therapy ; Anxiety/epidemiology ; Anxiety/pathology ; Breast/pathology ; Breast Neoplasms/drug therapy ; Breast Neoplasms/epidemiology ; Breast Neoplasms/pathology ; Depression/drug therapy ; Depression/epidemiology ; Depression/pathology ; Female ; Humans ; Involuntary Commitment ; Middle Aged ; Neoplasm Recurrence, Local/drug therapy ; Neoplasm Recurrence, Local/pathology ; Neoplasm Recurrence, Local/prevention & control ; Neoplasm Staging ; Phobic Disorders/drug therapy ; Phobic Disorders/epidemiology ; Phobic Disorders/pathology ; Quality of Life ; Stress Disorders, Post-Traumatic/complications ; Stress Disorders, Post-Traumatic/epidemiology ; Stress Disorders, Post-Traumatic/pathology ; Stress Disorders, Post-Traumatic/psychology
SCR Disease Name :
Phobia, Specific
Czasopismo naukowe
Tytuł :
Risk and subtypes of secondary primary malignancies in diffuse large B-cell lymphoma survivors change over time based on stage at diagnosis.
Autorzy :
Major A; Department of Medicine, Internal Medicine Residency Training Program, University of Colorado School of Medicine, Aurora, Colorado.
Smith DE; Department of Pediatrics, Cancer Center Biostatistics Core, University of Colorado School of Medicine, Aurora, Colorado.
Ghosh D; Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, Colorado.
Rabinovitch R; Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, Colorado.
Kamdar M; Department of Medicine, Division of Hematology, University of Colorado School of Medicine, Aurora, Colorado.
Pokaż więcej
Źródło :
Cancer [Cancer] 2020 Jan 01; Vol. 126 (1), pp. 189-201. Date of Electronic Publication: 2019 Sep 11.
Typ publikacji :
Journal Article
MeSH Terms :
Cancer Survivors*
Lymphoma, Large B-Cell, Diffuse/*epidemiology
Neoplasm Recurrence, Local/*epidemiology
Neoplasms, Second Primary/*epidemiology
Adolescent ; Adult ; Aged ; Female ; Humans ; Lymphoma, Large B-Cell, Diffuse/pathology ; Male ; Middle Aged ; Neoplasm Recurrence, Local/classification ; Neoplasm Recurrence, Local/pathology ; Neoplasm Staging ; Neoplasms, Second Primary/classification ; Neoplasms, Second Primary/pathology ; SEER Program ; Survivors ; Young Adult
Czasopismo naukowe
Tytuł :
Fertility preservation before breast cancer treatment appears unlikely to affect disease-free survival at a median follow-up of 43 months after fertility-preservation consultation.
Autorzy :
Letourneau JM; Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco School of Medicine, San Francisco, California.; Department of Obstetrics and Gynecology, University of Utah School of Medicine, Salt Lake City, Utah.
Wald K; Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco School of Medicine, San Francisco, California.
Sinha N; Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco School of Medicine, San Francisco, California.; Department of Obstetrics and Gynecology, Northwestern University School of Medicine, Chicago, Illinois.
Juarez-Hernandez F; Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco School of Medicine, San Francisco, California.
Harris E; Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco School of Medicine, San Francisco, California.
Cedars MI; Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco School of Medicine, San Francisco, California.
McCulloch CE; Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco School of Medicine, San Francisco, California.
Dolezal M; Hematology and Oncology, California Pacific Medical Center Research Institute, San Francisco, California.
Chien AJ; Department of Medicine, University of California San Francisco School of Medicine, San Francisco, California.
Rosen MP; Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California San Francisco School of Medicine, San Francisco, California.
Pokaż więcej
Źródło :
Cancer [Cancer] 2020 Feb 01; Vol. 126 (3), pp. 487-495. Date of Electronic Publication: 2019 Oct 22.
Typ publikacji :
Journal Article
MeSH Terms :
Breast Neoplasms/*drug therapy
Cryopreservation/*methods
Fertility Preservation/*adverse effects
Neoplasm Recurrence, Local/*drug therapy
Adult ; Breast Neoplasms/pathology ; Disease-Free Survival ; Female ; Fertility/genetics ; Follow-Up Studies ; Humans ; Neoadjuvant Therapy/methods ; Neoplasm Recurrence, Local/pathology ; Oocytes/growth & development ; Oocytes/transplantation ; Referral and Consultation ; Retrospective Studies
Czasopismo naukowe
Tytuł :
Soft-tissue sarcoma in adolescents and young adults compared with older adults: A report among 5000 patients from the Scandinavian Sarcoma Group Central Register.
Autorzy :
Papworth KE; Department of Radiation Sciences-Oncology, Umea University, Umea, Sweden.
Arroyo VM; Section of Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas.
Styring E; Department of Orthopedics, Skane University Hospital, Lund University, Lund, Sweden.
Zaikova O; Department of Orthopedic Oncology, the Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.
Melin BS; Department of Radiation Sciences-Oncology, Umea University, Umea, Sweden.
Lupo PJ; Section of Hematology-Oncology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas.
Pokaż więcej
Źródło :
Cancer [Cancer] 2019 Oct 15; Vol. 125 (20), pp. 3595-3602. Date of Electronic Publication: 2019 Jul 09.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Sex Characteristics*
Neoplasm Recurrence, Local/*epidemiology
Sarcoma/*epidemiology
Adolescent ; Adult ; Age Factors ; Aged ; Aged, 80 and over ; Female ; Humans ; Male ; Middle Aged ; Neoplasm Recurrence, Local/pathology ; Neoplasm Recurrence, Local/therapy ; Risk Factors ; Sarcoma/pathology ; Sarcoma/therapy ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Surgical excision, Mohs micrographic surgery, external-beam radiotherapy, or brachytherapy for indolent skin cancer: An international meta-analysis of 58 studies with 21,000 patients.
Autorzy :
Lee CT; Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Lehrer EJ; Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, New York.
Aphale A; Department of Dermatology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Lango M; Department of Surgery, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Galloway TJ; Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.
Zaorsky NG; Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.; Department of Radiation Oncology, Penn State Cancer Institute, Hershey, Pennsylvania.; Department of Public Health Sciences, Penn State College of Medicine, Hershey, Pennsylvania.
Pokaż więcej
Źródło :
Cancer [Cancer] 2019 Oct 15; Vol. 125 (20), pp. 3582-3594. Date of Electronic Publication: 2019 Jul 29.
Typ publikacji :
Journal Article; Meta-Analysis
MeSH Terms :
Mohs Surgery*
Neoplasm Recurrence, Local/*surgery
Skin Neoplasms/*surgery
Brachytherapy ; Combined Modality Therapy ; Female ; Humans ; Male ; Neoplasm Recurrence, Local/pathology ; Neoplasm Recurrence, Local/radiotherapy ; Neoplasm Staging ; Skin Neoplasms/pathology ; Skin Neoplasms/radiotherapy
Czasopismo naukowe
Tytuł :
Explicit prognostic disclosure to Asian women with breast cancer: A randomized, scripted video-vignette study (J-SUPPORT1601).
Autorzy :
Mori M; Palliative Care Team, Seirei Mikatahara General Hospital, Hamamatsu, Japan.; Division of Health Care Research, Behavioral Science and Survivorship Research Group, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan.
Fujimori M; Division of Health Care Research, Behavioral Science and Survivorship Research Group, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan.; Division of Cohort Consortium Research, Epidemiology and Prevention Group, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan.
van Vliet LM; Department of Communication, Nivel-Netherlands Institute for Health Services Research, Utrecht, Netherlands.; Department of Health, Medical, and Neuropsychology, Leiden University, Leiden, Netherlands.
Yamaguchi T; Division of Biostatistics, Tohoku University Graduate School of Medicine, Sendai, Japan.
Shimizu C; Department of Breast Medical Oncology, National Center for Global Health and Medicine, Shinjuku-ku, Japan.
Kinoshita T; Department of Breast Surgery, National Cancer Center Hospital, Tokyo, Japan.
Morishita-Kawahara M; Division of Health Care Research, Behavioral Science and Survivorship Research Group, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan.
Inoue A; Department of Palliative Medicine, Tohoku University School of Medicine, Sendai, Japan.
Inoguchi H; Department of Psycho-Oncology, National Cancer Center Hospital, Tokyo, Japan.
Matsuoka Y; Division of Health Care Research, Behavioral Science and Survivorship Research Group, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan.
Bruera E; Department of Palliative Care and Rehabilitation Medicine, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Morita T; Palliative and Supportive Care Division, Seirei Mikatahara General Hospital, Hamamatsu, Japan.
Uchitomi Y; Division of Health Care Research, Behavioral Science and Survivorship Research Group, Center for Public Health Sciences, National Cancer Center, Tokyo, Japan.; Innovation Center for Supportive, Palliative, and Psychosocial Care, National Cancer Center Hospital, Tokyo, Japan.
Pokaż więcej
Źródło :
Cancer [Cancer] 2019 Oct 01; Vol. 125 (19), pp. 3320-3329. Date of Electronic Publication: 2019 Jun 17.
Typ publikacji :
Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Physician-Patient Relations*
Truth Disclosure*
Anxiety/*diagnosis
Breast Neoplasms/*psychology
Neoplasm Recurrence, Local/*psychology
Adaptation, Psychological ; Advance Care Planning ; Anxiety/etiology ; Anxiety/psychology ; Asian Continental Ancestry Group/psychology ; Breast Neoplasms/diagnosis ; Breast Neoplasms/pathology ; Breast Neoplasms/therapy ; Communication ; Female ; Humans ; Japan ; Middle Aged ; Neoplasm Recurrence, Local/diagnosis ; Neoplasm Recurrence, Local/pathology ; Neoplasm Staging ; Patient Satisfaction ; Prognosis ; Self Efficacy ; Surveys and Questionnaires ; Treatment Outcome ; Uncertainty
Czasopismo naukowe
Tytuł :
Minor salivary gland tumors of the head and neck-Memorial Sloan Kettering experience: Incidence and outcomes by site and histological type.
Autorzy :
Hay AJ; Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Migliacci J; Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Karassawa Zanoni D; Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
McGill M; Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Patel S; Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Ganly I; Head and Neck Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
Pokaż więcej
Źródło :
Cancer [Cancer] 2019 Oct 01; Vol. 125 (19), pp. 3354-3366. Date of Electronic Publication: 2019 Jun 07.
Typ publikacji :
Journal Article
MeSH Terms :
Carcinoma, Mucoepidermoid/*epidemiology
Neoplasm Recurrence, Local/*epidemiology
Salivary Gland Neoplasms/*epidemiology
Salivary Glands, Minor/*pathology
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Carcinoma, Mucoepidermoid/pathology ; Disease-Free Survival ; Female ; Follow-Up Studies ; Humans ; Incidence ; Male ; Margins of Excision ; Middle Aged ; Neoplasm Recurrence, Local/pathology ; Neoplasm Recurrence, Local/prevention & control ; Neoplasm Staging ; Prognosis ; Radiotherapy, Adjuvant ; Retrospective Studies ; Salivary Gland Neoplasms/pathology ; Salivary Gland Neoplasms/therapy ; Salivary Glands, Minor/radiation effects ; Salivary Glands, Minor/surgery ; Survival Rate ; United States/epidemiology ; Young Adult
Czasopismo naukowe
Tytuł :
Usefulness of surveillance imaging in patients with head and neck cancer who are treated with definitive radiotherapy.
Autorzy :
Ng SP; Division of Radiation Oncology, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Pollard C 3rd; Division of Radiation Oncology, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Berends J; The University of Texas Health Science Center, San Antonio, Texas.
Ayoub Z; Division of Radiation Oncology, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Kamal M; Division of Radiation Oncology, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.; Department of Clinical Oncology, Ain Shams University, Cairo, Egypt.
Garden AS; Division of Radiation Oncology, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Bahig H; Division of Radiation Oncology, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Cantor SB; Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Schaefer AJ; Department of Computational and Applied Mathematics, Rice University, Houston, Texas.
Ajayi T; Department of Computational and Applied Mathematics, Rice University, Houston, Texas.
Gunn GB; Division of Radiation Oncology, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Frank SJ; Division of Radiation Oncology, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Skinner H; Division of Radiation Oncology, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Phan J; Division of Radiation Oncology, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Morrison WH; Division of Radiation Oncology, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Ferrarotto R; Division of Cancer Medicine, Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Johnson JM; Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Mohamed ASR; Division of Radiation Oncology, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Lai SY; Division of Surgery, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Hessel AC; Division of Surgery, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Sturgis EM; Division of Surgery, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Weber RS; Division of Surgery, Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Fuller CD; Division of Radiation Oncology, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Rosenthal DI; Division of Radiation Oncology, Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Pokaż więcej
Źródło :
Cancer [Cancer] 2019 Jun 01; Vol. 125 (11), pp. 1823-1829. Date of Electronic Publication: 2019 Feb 12.
Typ publikacji :
Journal Article
MeSH Terms :
Head and Neck Neoplasms/*diagnostic imaging
Head and Neck Neoplasms/*epidemiology
Neoplasm Recurrence, Local/*diagnostic imaging
Neoplasm Recurrence, Local/*epidemiology
Population Surveillance/*methods
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Early Detection of Cancer ; Female ; Head and Neck Neoplasms/radiotherapy ; Humans ; Male ; Middle Aged ; Neoplasm Recurrence, Local/radiotherapy ; Retrospective Studies ; Salvage Therapy ; Survival Analysis ; Time-to-Treatment ; Young Adult
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies